

Advaxis, Inc.
Form 8-K
August 08, 2005

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) August 8, 2005

Advaxis, Inc.

(Exact name of registrant as specified in its charter)

| | | |
|---------------------------------------------------------------|--------------------------------------|------------------------------------------------------|
| Delaware (State or other jurisdiction of incorporation) | 00028489 (Commission File Number) | 84 - 1521955 (IRS Employer Identification No.) |
|---------------------------------------------------------------|--------------------------------------|------------------------------------------------------|

| | |
|-------------------------------------------------------------------------------------|---------------------|
| 212 Carnegie Center #206, Princeton, NJ (Address of principal executive offices) | 08546 (Zip Code) |
|-------------------------------------------------------------------------------------|---------------------|

Registrant's telephone number, including area code (609) 497-7555

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events

On August 8, 2005, the Registrant announced that its GMP clinical materials had passed quality control release and is available for use in Advaxis' Phase I/II clinical trial of Lovaxin C in advance cervical cancer patients. See Registrant's press release attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

a) Not applicable.

b) Not applicable.

c) Exhibits

99.1. Press Release, dated August 8, 2005

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 8, 2005

ADVAXIS, INC.

By: /s/ J. Todd Derbin

Name: J. Todd Derbin
Title: President and Chief
Executive Officer